Mitomycin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Mitomycin: From Gastrointestinal Cancer to Solid Pseudopapillary Carcinoma of Pancreas
One-Sentence Summary
Mitomycin (Mitomycin C) is a DNA-crosslinking antineoplastic antibiotic historically used in gastrointestinal cancer chemotherapy regimens. The TxGNN model predicts it may be effective for Solid Pseudopapillary Carcinoma of Pancreas, but this specific prediction is currently supported by 0 clinical trials and 0 publications — it is a pure knowledge-graph inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no regulatory license record exists for this drug in the current dataset |
| Predicted New Indication | Solid Pseudopapillary Carcinoma of Pancreas |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L5 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for mitomycin is not available in this evidence pack (flagged as a data gap). Based on known drug-class information referenced elsewhere in this same evidence pack (see rank 8 rationale), mitomycin is a DNA cross-linking antineoplastic antibiotic that has historically been used as a component of combination chemotherapy regimens (e.g., FAM: 5-FU/Adriamycin/Mitomycin) for gastrointestinal malignancies, including pancreatic cancer.
For the top-ranked prediction, solid pseudopapillary carcinoma of pancreas, the TxGNN knowledge-graph similarity score is very high (99.86%), but no clinical trial or literature evidence currently links mitomycin to this specific tumor subtype. It is also worth noting for clinical context that solid pseudopapillary carcinoma is generally a low-grade, surgically curable pancreatic tumor, and systemic cytotoxic chemotherapy is not standard first-line management — this makes the mechanistic rationale for this particular candidate weaker than for other candidates in the same prediction set.
Notably, a lower-ranked candidate in this same evidence pack — “malignant exocrine pancreas neoplasm” (rank 8) — has materially stronger supporting evidence (L3, two literature citations including a review on exocrine pancreatic cancer chemotherapy), since mitomycin has documented historical use in general pancreatic exocrine cancer regimens. Reviewers may wish to prioritize that candidate over the top-ranked one when deciding where to invest further evaluation effort.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
Not marketed — no license records are available (market status: Not Marketed; total licenses: 0).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (DNA cross-linking antineoplastic antibiotic / alkylating-like agent) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (solid pseudopapillary carcinoma of pancreas) is supported only by a TxGNN similarity score (L5, S0) with no clinical trial or literature corroboration, and a blocking data gap exists for TFDA/FDA label warnings and contraindications, which prevents progression to safety initial screening (S1). The drug also has no current NDA/marketing record in this dataset.
To proceed, the following is needed:
- TFDA/FDA package insert data (warnings, contraindications) to clear the blocking data gap (DG001)
- Verified mechanism of action data from DrugBank or primary literature (DG002)
- Consider re-scoping evaluation priority toward rank 8 (“malignant exocrine pancreas neoplasm”), which already has L3 evidence and Research Question status
- Clinical trial or preclinical mechanistic studies specific to solid pseudopapillary carcinoma before any further advancement
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.